Hanneke Van Laarhoven

Hanneke Van Laarhoven

University of Amsterdam - Amsterdam / Netherlands
Others
AD Scientific Index ID: 1808034
Universiteit van Amsterdam
person_outline Hanneke Van Laarhoven's MOST POPULAR ARTICLES
1-) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trialJ Shapiro, JJB Van Lanschot, MCCM Hulshof, P van Hagen, ...The lancet oncology 16 (9), 1090-1098, 201518462015
2-) Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trialJ Van Hilst, T de Rooij, K Bosscha, DJ Brinkman, S van Dieren, ...The lancet Gastroenterology & hepatology 4 (3), 199-207, 20194532019
3-) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trialA Cats, EPM Jansen, NCT van Grieken, K Sikorska, P Lind, M Nordsmark, ...The lancet oncology 19 (5), 616-628, 20184562018
4-) Venous thromboembolism in cancer patients: a population-based cohort studyFI Mulder, E Horvàth-Puhó, N van Es, HWM Van Laarhoven, L Pedersen, ...Blood, The Journal of the American Society of Hematology 137 (14), 1959-1969, 20214722021
5-) Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trialBM Eyck, JJB van Lanschot, MCCM Hulshof, BJ van der Wilk, J Shapiro, ...Journal of Clinical Oncology 39 (18), 1995-2004, 20214682021